Abstract
Malignant neuroendocrine gut and pancreatic tumors present as specific clinical syndromes. Although these neoplasms advance slowly, the associated excess hormone production can result in severe symptoms. Clinical syndromes such as Zollinger-Ellison’s, Verner-Morrison’s, and carcinoid syndromes are related to the peptide secretions of these tumors. Most patients who present with clinical symptoms have metastases at the time of diagnosis. The ultimate treatment for malignant neuroendocrine gut and pancreatic tumors has still to be elucidated. Surgery has always been considered the primary treatment modality for these tumors [11], but when metastases have appeared, cure cannot be achieved. Resections of primary tumors and liver metastases, and other debulking procedures may lead to short remissions.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Eriksson B, Öberg K, Alm G, Lundqvist G, Magnusson A, Wide L, Wilander E: Treatment of malignant endocrine pancreatic tumors with human leukocyte interferon. Lancet 1986; ii:1307–1309
Eriksson B, Öberg K, Andersson T, Lundqvist G, Wide L, Wilander E: Treatment of malignant endocrine pancreatic tumors with a new somatostatin analogue, SMS 201–995. Scand J Gastroenterol 1988; 23: 508–512
Johansson H, Boström H, Öberg K: Treatment of malignant endocrine pancreatic tumors. Results from an Uppsala material. Ups J Med Sci 1984; [Suppl] 39:179–189
Kvols LK, Moertel CG, O’Connell MJ, Schutt AJ, Rubin J, Hahn RG: Treatment of the malignant carcinoid syndrome; evaluation of a long-acting somatostatin analogue. N Engl J Med 1986; 315, 11:663–666
Legha SW, Valdiveso M, Nelson RS, Benjamin RS, Bodey GP: Chemotherapy for metastatic carcinoid tumors. Experiences with 32 patients and a review of the literature. Cancer Treat Rep 1977; 61:1699–1703
Moertel CG, Hanley JA: Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Clin Trials 1979; 2:327
Moertel CG, Hanley JA, Johnson LA: Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet cell carcinoma. N Engl J Med 1980; 303:1189
Öberg K, Norheim I, Lind E, Jonsdottir B, Magnusson A, Lundqvist G, Wide L, Alm G: Treatment of malignant carcinoid tumors with human leukocyte interferon. Long-term results. Cancer Treat Rep 1986; 70:1297–1304
Öberg K, Norheim I, Theodersson E, Ahlmann H, Lundqvist G, Wide L: The effects of octreotide on basal and stimulated hormone levels in patients with carcinoid syndrome. J Clin Endocrinol Metab (in press)
Reichlin S: Somatostatin. N Engl J Med 1983; 309:1495–1501, 1556–1563
Welbourn RB: Apudomas of the gut. Am J Surg 1977; 133:13–22
Wood SM, Kraenzlin ME, Adrian TE, Bloom SR: Treatment of patients with pancreatic endocrine tumors using a new long-acting somatostatin analogue; symptomatic and peptide responses. Gut 1985; 26:438–444
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1989 Springer Verlag, Berlin Heidelberg
About this paper
Cite this paper
Öberg, K., Eriksson, B., Norheim, I. (1989). Treatment of Malignant Neuroendocrine Gut and Pancreatic Tumors with Sandostatin®. In: O’Dorisio, T.M. (eds) Sandostatin® in the Treatment of Gastroenteropancreatic Endocrine Tumors. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-61328-9_13
Download citation
DOI: https://doi.org/10.1007/978-3-642-61328-9_13
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-64794-9
Online ISBN: 978-3-642-61328-9
eBook Packages: Springer Book Archive